Palvella Therapeutics PVLA Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $1.07M+42.7% | $520K+85.1% | $628K+236% | $690K+902% | $752K+774% | ||
| $9.33M+129% | $7.12M+180% | $6.53M+105% | $5.12M+255% | $4.07M+314% | ||
| $5.52M+45.4% | $4.18M+129% | $3.65M+94.1% | $4.13M+182% | $3.8M+390% | ||
| $14.86M+88.7% | $11.3M+159% | $10.18M+101% | $9.25M+218% | $7.87M+347% | ||
| $14.86M+88.7% | $11.3M+159% | $10.18M+101% | $9.25M+218% | $7.87M+347% | ||
| -$14.86M-88.7% | -$11.3M-159% | -$10.18M-101% | -$9.25M-218% | -$7.87M-347% | ||
| -$32K-114% | —— | $34K+270% | $561K+777% | $224K— | ||
| -$15.77M-92.6% | -$12.71M-222% | -$11.35M-67.5% | -$9.47M-127% | -$8.19M-223% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| -$15.77M-92.6% | -$12.71M-222% | -$11.35M-67.5% | -$9.47M-127% | -$8.19M-223% | ||
| -$1.20-62.2% | -$1.08— | -$1.03+73.9% | -$0.86+65.2% | -$0.74+51.9% | ||
| -$1.20-62.2% | -$1.08— | -$1.03+73.9% | -$0.86+65.2% | -$0.74+51.9% | ||
| 13.1M+18.8% | 11.3M+405% | 11.1M+525% | 11.1M+524% | 11M+522% | ||
| 13.1M+18.8% | 11.3M+405% | 11.1M+525% | 11.1M+524% | 11M+522% | ||
| $202K— | —— | —— | —— | $0+100% | ||
| -$2.04M-67.8% | -$1.74M-54.9% | -$1.51M-48.5% | -$1.35M-43.7% | -$1.22M-50.9% | ||
| —— | $0-100% | $0-100% | $0-100% | $0-100% | ||
| -$15.76M-92.3% | -$12.74M-278% | -$11.13M-59.7% | -$9.58M-119% | -$8.19M-200% | ||
| $1.07M+42.7% | $520K+85.1% | $628K+236% | $690K+902% | $752K+774% | ||
| $8K+233% | —— | $215K— | -$108K— | -$6K— | ||
| -$32K-114% | —— | $34K+270% | $561K+777% | $224K— | ||
| -$116K-54.7% | -$119K+48.0% | -$82K-9.3% | -$118K+56.5% | -$75K-29.3% | ||
| -$14.86M-88.7% | -$11.3M-159% | -$10.18M-101% | -$9.25M-218% | -$7.87M-347% | ||
| —— | —— | —— | —— | —— | ||
| -$14.86M-88.7% | -$11.3M-159% | -$10.18M-101% | -$9.25M-218% | -$7.87M-347% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Palvella Therapeutics's revenue?
- Palvella Therapeutics (PVLA) generated $40.9M in revenue over the trailing twelve months, up 142.9% year over year.
- Is Palvella Therapeutics profitable?
- Palvella Therapeutics is not currently profitable: it reported a net loss of $49.3M over the trailing twelve months, a 71.7% net margin.
- What is Palvella Therapeutics's earnings per share?
- Palvella Therapeutics's diluted EPS over the trailing twelve months is $-4.17.
- Where does Palvella Therapeutics's income statement data come from?
- Every line is extracted from Palvella Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
